FUS-DDIT3 is a chimeric oncogene generated by the most com-15 mon chromosomal translocation t(12;16)(q13;p11) associated to liposarcomas. The application of transgenic methods and the use of primary mesenchymal progenitor cells to the study of this sarcoma-associated FUS-DDIT3 gene fusion have provided insights into their in vivo functions and suggested mechanisms by which 20 lineage selection may be achieved. These studies indicate that FUS-DDIT3 contributes to differentiation arrest acting at a point in the adipocyte differentiation process after induction of peroxisome proliferator-activated receptor g (PPARg) expression. To test this idea within a living mouse, we generated mice expressing 25 FUS-DDIT3 within aP2-positive cells, because aP2 is a downstream target of PPARg expressed at the immature adipocyte stage. Here, we report that FUS-DDIT3 expression was successfully induced at the aP2 stage of differentiation both in vivo and in vitro. aP2-FUS-DDIT3 mice do not develop liposarcomas and ex-30 hibit an increase in white adipose tissue size. Consistent with in vivo data, mouse embryonic fibroblasts (MEFs) obtained from aP2-FUS-DDIT3 mice not only were capable of terminal differentiation but also showed an increased capacity for adipogenesis in vitro compared with wild-type MEFs. Taken together, this study 35 provides genetic evidence that the presence of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposarcoma development and establishes that PPARg inactivation is required for liposarcoma development.
Introduction
40 Myxoid/round cell liposarcoma is the most common subtype of liposarcoma, accounting for $40% of all cases. The tumor cells are characterized by the chromosomal aberration t(12;16)(q13;p11), which creates the FUS-DDIT3 oncogene (1) (2) (3) (4) . This fusion oncogene has not been found in tumor types other than myxoid/round cell lip-45 osarcoma (4, 5) . Due to the absence of a direct link between a cell carrying the cytogenetic abnormality and a test of whether this cell has the capacity to maintain the disease in vivo, the nature of the intimate association between the FUS-DDIT3 oncogene and the phenotype with which it is associated is pending to understand (6) (7) (8) . In 50 vitro the transforming effects of FUS-DDIT3 have been demonstrated in fibroblasts (9) , but curiously not in 3T3-L1 cells under conditions expected to yield oncogenic effects (10) , suggesting that the function of FUS-DDIT3 is influenced by cell environment. Consistent with this notion, transgenic mice engineered to express FUS-DDIT3 under the 55 control of the ubiquitous E1Fa promoter, which has found to be functional in mesenchymal progenitor/stem cells (11) , developed liposarcomas that resemble their human counterpart (9, 12, 13) . In agreement with this view is the genomic analysis carried out in human myxoid liposarcoma (14) , which is compatible with the genetic pro-
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gram of a primitive target cell from which myxoid liposarcoma could arise. Further support to this idea comes from the studies showing that the expression of FUS-DDIT3 in primary mesenchymal progenitor cells give rise to myxoid liposarcoma-like tumors (11, 15) . Taken together, these data indicate that FUS-DDIT3-liposarcoma develops from uncommitted progenitor cells (7, 8) . However, the observation that FUS-DDIT3 has been previously reported to block terminal differentiation of pre-adipocytes in vivo and in vitro (10,16) calls this hypothesis into question. These reports lead to the hypothesis that liposarcoma develops from pre-adipocytes carrying FUS-DDIT3 that 70 are incapable of terminal differentiation. While the precise nature of the developmental defect in liposarcoma is not yet clear, it is likely FUS-DDIT3 ultimately leads to the inactivation or antagonism of one or more adipocyte transcriptional regulatory proteins. The proposed effect of FUS-DDIT3 on peroxi-75 some proliferator-activated receptor c (PPARc) activity (9, 12, 13, 16) close to the absence of PPARc induction in mesenchymal progenitor/ stem cells expressing FUS-DDIT3 (11) has suggested that FUS-DDIT3 contributes to differentiation arrest acting at a point in the adipocyte differentiation process after induction of PPARc expres-80 sion. In order to test this idea and because aP2 is a downstream target of PPARc (17) which is expressed at the immature adipocyte stage (18, 19) , we have generated mice targeting FUS-DDIT3 expression to aP2-positive cells.
Materials and methods
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Generation of transgenic mice The cDNA for human FUS-DDIT3 was cloned under the control of the 5.4 kb aP2 gene promoter for fat-specific FUS-DDIT3-transgenic mice (20) to give rise to aP2-FUS-DDIT3 cassette. Linear DNA fragments for microinjection were obtained and injected by the University of Salamanca Transgenic Facility 90 into CBA Â C57BL/6J fertilized eggs. We identified transgenic mice by Southern analysis of tail snip DNA after HindIII digestion as described (21) . We used the human DDIT3 cDNA for detection of the transgene. Similar phenotypic features were seen in all assays for both the aP2-FUS-DDIT3-transgenic lines generated.
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Reverse transcription-polymerase chain reaction
To analyze expression of human FUS-DDIT3 in mouse tissues and mouse embryonic fibroblasts (MEFs), reverse transcription was performed according to the manufacturer's protocol in a 20 ll reaction containing 50 ng of random hexamers, 3 lg of total RNA and 200 U of Superscript II RNase H À reverse 100 transcriptase (Gibco BRL, Madrid, Spain). The sequences of the specific primers were as follows: FUS-F1: 5#-GGTTATGGCAATCAAGACCAG-3# and DDIT3-B1: 5#-CTTGCAGGTCCTCATACCAGG-3#. This oligo pair amplifies specifically the fusion region. The thermocycling parameters for the polymerase chain reaction and the sequences of the specific primers were as 105 follows: 30 cycles at 94°C for 1 min, 60°C for 1 min and 72°C for 1 min. The polymerase chain reaction products were confirmed by hybridization with specific probes. Amplification of aP2 and 36B4 served as a control to assess the adipose tissue and the quality of each RNA sample, respectively.
Histological analysis
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Mice included in this study were subjected to standard necropsy. All major organs were closely examined under the dissecting microscope, and samples of each organ were processed into paraffin, sectioned and examined histologically. All tissue samples were taken from homogenous and viable portions of the resected sample by the pathologist and fixed within 2-5 min of excision.
Hematoxylin-and eosin-stained sections of each tissue were reviewed by a single pathologist (T.F.). For comparative studies, age-matched mice were used (wild-type versus aP2-FUS-DDIT3 mice).
Abbreviations: BAT, brown adipose tissue; MEF, mouse embryonic fibroblast; PBS, phosphate-buffered saline; PPARc, peroxisome proliferator-activated receptor c WAT, white adipose tissue. 
Adipocyte differentiation
Wild-type and aP2-FUS-DDIT3 MEFs were cultured at 37°C in standard D-MEM:F12 medium (Gibco BRL) supplemented with 10% heat-inactivated 135 fetal bovine serum (Hyclone, Madrid, Spain), 100 U/ml penicillin (BioWhittaker, Madrid, Spain) and 100 lg/ml streptomycin (BioWhittaker, Madrid, Spain). Cells (10 6 ) of each genotype were plated to 10 cm plastic dishes and propagated to confluence. Two days after confluence, the adipocyte differentiation program was induced by feeding the cells with standard medium supplemented 140 with 0.5 mM 3-isobutyl-1-methylxanthine (Sigma, Madrid, Spain), 1 lM dexamethasone (Sigma) and 5 lg/ml insulin (Sigma) for two days, and then with standard medium supplemented with 5 lg/ml insulin for 6 days. This medium was renewed every 2 days. 150 RNA extraction Total RNA was isolated in two steps using TRIzol (Life Technologies, Grand Island, NY) followed by Rneasy Mini-Kit (Qiagen, Valencia, CA) purification following the manufacturer's RNA clean-up protocol with the optional oncolumn Dnase treatment. The integrity and the quality of RNA were verified 155 by electrophoresis and its concentration was measured.
Northern blot analysis
Total cytoplasmic RNA (10 lg) of aP2-FUS-DDIT3 MEFs harvested at days 0, 2, 4 and 8 of differentiation and three tumor tissues developed in E1Fa-FUS-DDIT3-transgenic mice were glyoxylated and fractionated in 1.4% agarose 160 gels in 10 mM Na 2 HPO 4 buffer (pH 7.0). After electrophoresis, the gel was blotted onto Hybond-N (Amersham, Madrid, Spain), UV cross-linked and hybridized to 32 P-labeled DDIT3 and aP2 probes, respectively. Loading was monitored by reprobing the filter with a mouse 36B4 probe. 165 To test the tumorigenicity of control and aP2-FUS-DDIT3 MEFs at day 2 after hormonal induction, 4-to 6-week old athymic (nude) male mice were injected subcutaneously on both flanks with 10 6 cells re-suspended in 200 ll of PBS. The animals were examined for tumor formation every week.
Tumorigenicity assay
Western blot analysis
170 Western blot analysis of white adipose tissue (WAT) was carried out. Extracts were normalized for protein content by Bradford analysis (Bio-Rad Laboratories, Melville, NY) and Coomassie blue gel staining. Lysates were run on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and transferred to a polyvinylidene difluoride membrane. After blocking, the mem-175 brane was probed with the following primary antibodies: PPARc (H-100 and E-8, Santa Cruz Biotechnology, Madrid, Spain), RXRa (D-20, Santa Cruz Biotechnology), C/EBPb (C-19, Santa Cruz Biotechnology), C/EBPd (M-17, Santa Cruz Biotechnology), C/EBPa (14AA, Santa Cruz Biotechnology) and actin (I-19, Santa Cruz Biotechnology). Reactive bands were detected with an 180 enhanced chemiluminescence system (Amersham).
Results and discussion
The mouse 5.4 kb promoter fragment of the aP2 gene (20) was used to drive aP2-directed expression of a human FUS-DDIT3 transgene in C57BL/6 Â CBA mice (aP2-FUS-DDIT3 mice) ( Figure 1A and B) . 185 This promoter is well characterized, and the fragment used contains all the necessary elements to recapitulate endogenous aP2 gene expression (20). Thus, by using the aP2 promoter, any possibility that embryonic expression of FUS-DDIT3 might interfere with development was minimized. The FUS-DDIT3 over-expressing animals have 190 normal gestation, birth and litter sizes, and they were viable. A number of founders were generated and two independent lines were obtained. Both lines were used to examine the phenotype further. Polymerase chain reaction with reverse transcriptase of messenger RNA for the human transgene confirmed that expression was largely liposarcomas (9) . Although liposarcomas did not develop in the aP2-FUS-DDIT3-transgenic mice, the total body weight of adult aP2-FUS-DDIT3 mice (34.3 ± 1.7 g) was increased compared with age-matched control mice (29.7 ± 1.2). We investigated whether the FUS-DDIT3 expression in aP2-positive cells altered WAT develop-210 ment in these mice. We analyzed WAT mass in aP2-FUS-DDIT3 mice. aP2-FUS-DDIT3 mice showed a large increase in WAT weight (Table I ). In addition, food intake was similar in wild-type (2.9 ± 0.4 g per mouse per day) and aP2-FUS-DDIT3 mice (2.8 ± 0.5 g per mouse per day). This overall increase in adipose tissue in aP2-FUS-DDIT3 215 mice was observed in males and females (Table I) . Although white fat is a non-malignant tissue, it has the capability to quickly proliferate and expand (22, 23) . Thus, FUS-DDIT3 expression under aP2 control regions is inducing those effects. In contrast to WAT, other tissues including the interscapular BAT and kidney had similar weights for 220 wild-type and aP2-FUS-DDIT3 mice (Table I) .
To further characterize the phenotype of adipose tissue, we examined histological sections of WAT and BAT (Figure 2A) . We observed no difference between the wild-type and aP2-FUS-DDIT3 mice in the BAT and WAT tissues. The histological analyses of the WAT in aP2-
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FUS-DDIT3 mice did not evidence any pathological change within the terminally differentiated adipocytes. On the contrary, aP2-FUS-DDIT3 mice had a normal architecture of the tissue and we did not observe any shift in the WAT toward immature in the aP2-FUS-DDIT3 mice. Some aP2-FUS-DDIT3 animals presented adipocytic accumulation in 230 liver ( Figure 2B) . The above results support the hypothesis that FUS-DDIT3 expression modulates adipose tissue size. To further explore the molecular basis through which FUS-DDIT3 expression in aP2-positive cells impairs the development of fat tissue, we examined the expression levels of the proteins responsible for WAT development.
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The expression of RXRa, C/EBPd, C/EBPb, PPARc and C/EBPa was not affected ( Figure 2C ). The adipogenesis of MEFs by hormonal induction is a wellestablished model system for the study of adipocyte differentiation in vitro (19) . To further examine the contribution of FUS-DDIT3 to 240 adipogenesis, we isolated MEFs from day 13.5 of aP2-FUS-DDIT3 and control embryos (Figure 3) . FUS-DDIT3 expression is not present in uncommitted progenitor cells before differentiation treatment (Figure 3A) . However, the amount of FUS-DDIT3 mRNA was apparent within 2 days and increased in abundance in parallel to aP2 expression 245 ( Figure 3A) . These results indicate that aP2-FUS-DDIT3 is tightly controlled temporally and spatially during differentiation of uncommitted mesenchymal cells. At day 8 after hormonal induction, there is lipid accumulation in control MEFs (20-30%). However, there was extensive accumulation in aP2-FUS-DDIT3 MEFs (45-55%) ( Figure   250 3B). The amount of FUS-DDIT3 mRNA in aP2-FUS-DDIT3 was similar to the expression of FUS-DDIT3 in tumors of E1Fa-FUS-DDIT3 mice ( Figure 3C ). To test the putative malignant nature of these cells, 1 Â 10 6 aP2-FUS-DDIT3 MEFs at day 2 after hormonal induction (when the amount of FUS-DDIT3 mRNA was apparent) 255 were injected subcutaneously into 40-day-old nude mice. Mice injected resulted in no tumors. These results show that adipocyte differentiation was not blocked in MEFs derived from aP2-FUS-DDIT3-transgenic mice treated with adipogenic hormones and confirm that interference with the normal process of differentiation contributes to 260 the oncogenic potential of FUS-DDIT3 fusion protein (9). Fat-specific FUS-DDIT3-transgenic mice
In conclusion, this study provides genetic evidence that the presence of FUS-DDIT3 in an aP2-positive cell is not enough to cause liposarcoma development and these cells are capable of terminal differentiation, underscoring the relevance of relationship between FUS-DDIT3 265 and the cell environment. Moreover, although it has been suggested that FUS-DDIT3 transforms at a point in the differentiation process after induction of PPARc expression, our findings further establish that PPARc inactivation is required for liposarcoma development. The precise mechanism whereby FUS-DDIT3 contributes to PPARc inactiva-270 tion and differentiation arrest, however, remain to be elucidated. 
